Sam Kwon

Mr. Sam Kwon


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 February 2026 in BJUI Compass
Verified
Journal Article
Open access
SKSam Kwon
Sam Kwon
FWFiona Wardrop
Fiona Wardrop
DGDiego Gonzalez
Diego Gonzalez
FRFrancis Ryan
Francis Ryan
LKLiza Khutsishvili
Liza Khutsishvili
MWMichael J. Whalen
Michael J. Whalen
Objectives: The purpose of this study is to investigate the impact of Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) use on 90‐day postoperative outcomes and overall survival following partial nephrectomy (PN) for renal cell carcinoma (RCC), where type 2 diabetes mellitus (T2DM) is a common comorbidity. Materials and Methods: The TriNetX database was used to retrospectively identify T2DM patients who underwent PN. Patients prescribed GLP‐1RAs were identified and matched in a 1:1 ratio with control patients who were not prescribed GLP‐1RAs based on baseline characteristics, comorbidities, metformin and insulin prescription, and renal function laboratory values. For 90‐day postoperative adverse events, risk difference, risk ratio and odds ratio with 95% confidence intervals were calculated. Kaplan–Meier analysis, log‐rank tests and multivariable Cox Proportional Hazards model were performed to measure the effect of GLP‐1RAs use on overall survival. Results: Use of GLP‐1RAs was associated with lower odds of acute kidney injury (odds ratio [OR] = 0.712), arrhythmia (OR = 0.725), readmission (OR = 0.8) and ileus (OR = 0.336) compared to the non‐GLP‐1RAs group ( p < 0.05 for each). Kaplan–Meier analysis and log‐rank tests demonstrated improved 2‐year ( p = 0.002) and 3‐year ( p = 0.001) overall survival among patients prescribed GLP‐1RAs compared to those who were not. Conclusion: Use of GLP‐1RAs was associated with reduced incidence of 90‐day postoperative complications, such as acute kidney injury, arrhythmia, readmission and ileus, potentially contributing to improved overall survival. These results align with ongoing studies investigating the broader benefits of the use of GLP‐1RAs.

1 July 2026 in Urology Case Reports
Verified
Journal Article
Open access
SKSam Kwon
Sam Kwon
TNTali Newman
Tali Newman
FWFiona Wardrop
Fiona Wardrop
KZKatherine Zhong
Katherine Zhong
JDJosiah Dallmer
Josiah Dallmer
MWMichael Whalen
Michael Whalen
Chromophobe renal cell carcinoma (ChRCC) is a renal malignancy typically associated with indolent behavior, with nodal involvement being rare. We report a 78-year-old African American male with incidentally discovered node-positive (pN+) ChRCC with sarcomatoid differentiation who developed spinal metastases despite adjuvant pembrolizumab. Histopathologic evaluation demonstrated distinct plant-like cell membranes, while genomic profiling revealed CDK4 amplification and MTAP and CDKN2A alterations associated with aggressive tumor biology. Notably, the tumor also exhibited additional unique molecular alterations that have not been previously reported in the literature.

25 July 2026 in Clinical Genitourinary Cancer
Verified
Journal Article
Closed access
SKSam Kwon
Sam Kwon
DGDIEGO GONZALEZ
DIEGO GONZALEZ
FWFiona Wardrop
Fiona Wardrop
TNTali Newman
Tali Newman
JDJosiah Dallmer
Josiah Dallmer
MWMichael J. Whalen
Michael J. Whalen